Myrexis, Inc. (MYRX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 4.01: the stock has moved about 301% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMyrexis, Inc. (MYRX) trades at $0.0008. Myrexis, Inc. is a financial services company focused on identifying and investing in life sciences assets. Formerly Myriad Pharmaceuticals, the company shifted its focus to financial investments in 2010. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for MYRX: MYRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Myrexis, Inc. (MYRX) Financial Services Profile
Myrexis, Inc., a shell company in the financial services sector, concentrates on identifying and making financial investments in life sciences assets. Formerly a pharmaceutical company, it transitioned to its current investment-focused model in 2010, operating with a minimal workforce from its New York headquarters.
What Is the Investment Thesis for MYRX?
Myrexis, Inc. presents a unique investment case as a shell company focused on life sciences investments. With a market capitalization of $0.00B and a negative P/E ratio, the company's financial performance is currently not indicative of profitability. The high beta of 4.01 suggests significant volatility relative to the market. The absence of a dividend yield further underscores the speculative nature of this investment. Potential value drivers include successful identification and capitalization on promising life science assets. However, the company's small size, limited resources, and reliance on a single employee pose significant risks. Future growth hinges on the company's ability to execute its investment strategy effectively and generate returns from its life science holdings. Investors should carefully consider the speculative nature and high-risk profile associated with Myrexis, Inc.
Based on FMP financials and quantitative analysis
MYRX Key Highlights
Market capitalization of $0.00B indicates a very small company size.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Beta of 4.01 suggests high volatility compared to the overall market.
- No dividend yield indicates that the company does not distribute profits to shareholders.
- Focus on life sciences investments provides exposure to a potentially high-growth sector.
Who Are MYRX's Competitors?
MYRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CIIT Tianci International, Inc. | $2.39 | +3.67% | 32 5-pillar | |
| COLA Columbus Acquisition Corp | $2.86 | -60.82% | $12.9M | 44 5-pillar |
| ASPC A SPAC III Acquisition Corp. | $10.82 | +0.28% | $25.3M | 48 5-pillar |
| RIBB Ribbon Acquisition Corp | $7.11 | +10.06% | $35.7M | 43 5-pillar |
| AFJK Aimei Health Technology Co., Ltd | $12.12 | -1.86% | $38.3M | 43 5-pillar |
| BKHA Black Hawk Acquisition Corporation | $13.00 | +5.86% | $51.3M | 51 5-pillar |
| WSTN Westin Acquisition Corp | $10.25 | +0.49% | $61.7M | 53 5-pillar |
| FVN Future Vision II Acquisition Corp. | $9.00 | -3.12% | $68.0M | 43 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MYRX's Key Strengths?
Focused investment strategy in the life sciences sector.
- Small and agile organizational structure.
- Historical expertise in pharmaceuticals.
- Potential for high returns from successful life science investments.
What Are MYRX's Weaknesses?
Limited financial resources.
- Reliance on a single employee.
- Lack of diversification in investment portfolio.
- Dependence on the success of underlying life science assets.
What Are the Key Risks for MYRX?
Negative return on equity (-25.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Limited financial resources may constrain the company's ability to pursue attractive investment opportunities.
- Reliance on a single employee poses a significant operational risk.
- The success of the company is dependent on the performance of its underlying life science investments.
- Market volatility and economic downturn could negatively impact the value of the company's investments.
- The company's OTC Other status presents increased risks due to limited regulation and disclosure.
What Threats Does MYRX Face?
- Market volatility and economic downturn.
- Regulatory changes and healthcare reforms.
- Competition from other investment firms.
- Failure of underlying life science assets to achieve commercial success.
What Are MYRX's Competitive Advantages?
- Focused expertise in life sciences: Myrexis's historical background in pharmaceuticals provides a knowledge base for evaluating investments.
- Agility and flexibility: As a small company, Myrexis can make investment decisions quickly.
- Network within the life sciences industry: Relationships with scientists and industry experts provide access to deal flow.
What Does MYRX Do?
Myrexis, Inc., headquartered in New York City, operates within the financial services sector as a shell company. The company's primary focus is to identify, evaluate, and make financial investments in life sciences assets. Originally established as Myriad Pharmaceuticals, Inc., the company underwent a strategic shift in July 2010, rebranding itself as Myrexis, Inc. to reflect its new direction. This transition marked a departure from pharmaceutical development and a move towards financial investments. Since its transformation, Myrexis has maintained a lean operational structure, with a single employee managing its investment activities. The company's investment strategy centers on seeking opportunities within the life sciences sector, aiming to capitalize on promising assets and technologies. While the company's history includes a background in pharmaceutical research and development, its current activities are solely focused on financial investments. Myrexis's small size and specific investment focus differentiate it from larger, more diversified financial institutions. The company's success depends on its ability to identify and secure profitable investments within the competitive life sciences landscape.
What Products and Services Does MYRX Offer?
- Identifies potential investment opportunities within the life sciences sector.
- Evaluates the financial and scientific merits of life science assets.
- Makes financial investments in promising life science companies and technologies.
- Manages its portfolio of life science investments.
- Seeks to generate returns through the growth and commercialization of its investments.
- Operates as a shell company with a focus on financial investments.
How Does MYRX Make Money?
- Myrexis generates revenue through capital appreciation of its investments in life sciences assets.
- The company seeks to identify and invest in undervalued or high-growth potential opportunities.
- Returns are realized through the sale of investments or through dividends and other distributions.
What Industry Does MYRX Operate In?
Myrexis, Inc. operates within the shell company segment of the financial services industry. Shell companies are often characterized by their lack of active business operations and are typically used for investment or acquisition purposes. The financial services industry is subject to regulatory scrutiny and market volatility, influencing the operations of shell companies. The competitive landscape includes other shell companies and investment firms seeking opportunities in various sectors. Myrexis's focus on life sciences investments differentiates it within this broader landscape.
Who Are MYRX's Key Customers?
- Myrexis's 'customers' are the investors who provide capital for its investment activities.
- The company aims to generate returns for its investors through successful life science investments.
- Myrexis does not have traditional customers in the sense of selling products or services.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Myrexis, Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in New York City, US. The company is led by CEO Jonathan Couchman. MYRX has traded publicly since 2009.
Key Financial Metrics
Return on equity for Myrexis, Inc. stands at -25.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 16.72 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Myrexis, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
Myrexis, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 6.9% above estimates on average.
Insider Activity
12 transactions · 0 purchases, 2 sales, 10 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
MYRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
MYRX Latest News
No recent news available for MYRX.
MYRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MYRX.
Price Targets
Wall Street price target analysis for MYRX.
MYRX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MYRX; grades run from A+ (80-100) to F (below 30).
Leadership: Jonathan Couchman
Managing Employee
Jonathan Couchman serves as the managing employee of Myrexis, Inc. As the sole employee, he is responsible for overseeing all aspects of the company's operations, including identifying investment opportunities, conducting due diligence, and managing the investment portfolio. His role requires a broad understanding of the life sciences sector and financial markets.
Track Record: Due to the limited information available and the company's small size, it is not possible to assess Jonathan Couchman's track record in detail. His performance is directly tied to the success of Myrexis's investment strategy and the returns generated from its life science holdings. The company's financial performance provides some indication of his effectiveness, but further information is needed for a comprehensive evaluation.
MYRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and are often subject to greater risks and volatility. Unlike NYSE or NASDAQ listings, OTC Other stocks do not have to meet minimum financial standards, governance requirements, or listing qualifications, resulting in less investor protection and increased potential for fraud or manipulation. Investors should exercise extreme caution when considering investments in this tier.
- OTC Tier: OTC Other
- Limited or no financial disclosure increases the risk of investing in MYRX.
- Low liquidity and wide bid-ask spreads can result in significant trading costs.
- Potential for price manipulation due to low trading volume.
- Lack of regulatory oversight compared to listed exchanges.
- Higher risk of fraud or mismanagement.
- Verify the company's legal standing and registration.
- Attempt to obtain and review any available financial statements.
- Research the background and experience of the company's management.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in existence since before 2010.
- Company has a registered address in New York.
- Company is focused on financial investments.
Common Questions About MYRX (Financials)
What do analysts say about MYRX stock?
There is currently no available analyst coverage for Myrexis, Inc. due to its OTC Other status and small market capitalization. Investors should conduct their own thorough research and consider the risks associated with investing in this stock.
What are the main risks for MYRX?
The main risks for Myrexis, Inc. include its limited financial resources, reliance on a single employee, and dependence on the success of its underlying life science investments. The company's OTC Other status presents increased risks due to limited regulation and disclosure.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is limited due to the company's OTC Other status and lack of financial disclosure.
- Analysis is based on publicly available information and may not be comprehensive.